Celastrol is an active compound extracted from the root bark of the traditional Chinese medicine Tripterygium wilfordii Hook F. In this study, we investigated the effect of celastrol on lipopolysaccharide (LPS)-activated LP-1 human multiple myeloma cell-induced angiogenesis, and identified its molecular mechanism of action. Migration of human umbilical vein endothelial cells (HUVECs) was tested using a wound-healing assay. HUVEC invasion was assayed using a Transwell chamber. Cell surface expression of Toll-like receptor 4 (TLR4) was analyzed by flow cytometry. Angiogenic factor vascular endothelial growth factor (VEGF) level was quantified by LUMINEX and protein expression was analyzed by Western blot. Translocation of nuclear factor-kappa B (NF-κB) was observed by fluorescence microscopy. Celastrol inhibited LPS-stimulated LP-1 human multiple myeloma-induced HUVEC migration and invasion in a concentration-dependent manner. Wound diameters increased by 72.9, 165.4 and 246.2% at 0.025, 0.05 and 0.1 µM, respectively, compared to LPS alone. A 45-74% inhibition of LPS-dependent cell invasion was achieved in the presence of 0.025-0.1 µM celastrol. Celastrol significantly downregulated LPS-induced TLR4 expression and inhibited LPS-induced VEGF secretion in LP-1 cells. VEGF levels decreased by 64.8, 84.4 and 92.9% after coexposure to celastrol at 0.025, 0.05 and 0.1 µM, respectively, compared to LPS alone. Celastrol also inhibited the IκB kinase (IKK)/NF-κB pathway induced by LPS. Protein levels of NF-κB p65, IKKa and IκB-a decreased in a dose-dependent manner after coexposure to celastrol. Celastrol also blocked nuclear translocation of the p65 subunit. These results suggest that celastrol inhibits LPS-induced angiogenesis by suppressing TLR4-triggered NF-κB activation.

Keywords:
Celastrol, Human multiple myeloma, Angiogenesis, Toll-like receptor 4, Nuclear factor-kappa B
1.
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC: Multiple myeloma. Lancet 2009;374:324-339.
2.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008;454:436-444.
3.
Kyle RA, Rajkumar SV: Multiple myeloma. Blood 2008;111:2962-2972.
4.
Jacobson DR, Zolla-Pazner S: Immunosuppression and infection in multiple myeloma. Semin Oncol 1986;13:282-290.
5.
Seidl S, Kaufmann H, Drach J: New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-564.
6.
Lauta VM: A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;97:2440-2452.
7.
Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-430.
8.
Gupta SC, Kim JH, Prasad S, Aggarwal BB: Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010;29;405-434.
9.
Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;47:149-161.
10.
Cao Y: Tumor angiogenesis and molecular targets for therapy. Front Biosci 2009;14:3962-3973.
11.
Pandya NM, Dhalla NS, Santani DD: Angiogenesis - a new target for future therapy. Vascul Pharmacol 2006;44:265-274.
12.
Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
13.
Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860-867.
14.
Bohnhorst J, Rasmussen T, Moen SH, Flottum M, Knudsen L, Borset M, Espevik T, Sundan A: Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006;20:1138-1144.
15.
Wang XY, Sarkar D, Fisher PB: Stress-sensing Toll-like receptor as a driver of angiogenesis. Pigment Cell Melanoma Res 2011;24:7-9.
16.
Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C: Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006;20:1130-1137.
17.
Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006;66:3859-3868.
18.
Feinman R, Siegel DS, Berenson J: Regulation of NF-κB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol 2004;2:162-166.
19.
O'Neill LA: How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006;18:3-9.
20.
Takeda K, Akira S: TLR signaling pathways. Semin Immunol 2004;16:3-9.
21.
Kannaiyan R, Shanmugam MK, Sethi G: Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 2011;303:9-20.
22.
Yang HS, Kim JY, Lee JH, Lee BW, Park KH, Shim KH, Lee MK, Seo KI: Celastrol isolated from Tripterygium regelii induces apoptosis through both caspase-dependent and -independent pathways in human breast cancer cells. Food Chem Toxicol 2011;49:527-532.
23.
Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, Liu M, Chaturvedi MM, Aggarwal BB: Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl) 2010;88:1243-1253.
24.
Dai Y, Desano J, Tang W, Meng X, Meng Y, Burstein E, Lawrence TS, Xu L: Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 2010;5:e14153.
25.
Yang H, Chen D,Cui QC , Yuan X, Dou QP: Celastrol, a triterpene extracted from the Chinese ‘Thunder of God Vine,' is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006;66:4758-4765.
26.
He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z, Duan W, Zhong L, Ye D, Chen W: The NF-kappaB inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009;9:343.
27.
Huang Y, Zhou Y, Fan Y, Zhou D: Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008;264:101-106.
28.
Chen M, Rose AE, Doudican N, Osman I, Orlow SJ: Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res 2009;7:1946-1953.
29.
Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N: Apoptosis induction in HL-60 Cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 2003;67:1883-1887.
30.
Li Z, Yao L, Li J, Zhang W, Wu X, Liu Y, Lin M, Su W, Li Y, Liang D: Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats. Int J Nanomed 2012;7:1163-1173.
31.
Huang L, Zhang Z, Zhang S, Ren J, Zhang R, Zeng H, Li Q, Wu G: Inhibitory action of celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1alpha pathway. Int J Mol Med 2011;27:407-415.
32.
Zhou YX, Huang YL: Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J (Engl) 2009;122:1666-1673.
33.
He MF, Liu L, Ge W, Shaw PC, Jiang R, Wu LW, But PP: Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J Ethnopharmacol 2009;121:61-68.
34.
Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB, Liu M: Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 2010;70:1951-1959.
35.
Huang S, Tang Y, Cai X, Peng X, Liu X, Zhang L, Xiang Y, Wang D, Wang X, Pan T: Celastrol inhibits vasculogenesis by suppressing the VEGF-induced functional activity of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 2012;423:467-472.
36.
Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-2756.
37.
Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M: Acetyl-11-keto-beta-Boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009;69:5893-5900.
38.
Min JK, Han KY, Kim EC, Kim YM, Lee SW, Kim OH, Kim KW, Gho YS, Kwon YG: Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 2004;64:644-651.
39.
Tadema H, Abdulahad WH, Stegeman CA, Kallenberg CG, Heeringa P: Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis. PLoS One 2011;6:e24315.
40.
Madsen CV, Steffensen KD, Olsen DA, Waldstrom M, Smerdel M, Adimi P, Brandslund I, Jakobsen A: Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. J Ovarian Res 2012;5:23.
41.
Huang C, Ding G, Gu C, Zhou J, Kuang M, Ji Y, He Y, Kondo T, Fan J: Decreased selenium-binding protein 1 enhances glutathione peroxidase 1 activity and downregulates HIF-1alpha to promote hepatocellular carcinoma invasiveness. Clin Cancer Res 2012;18:3042-3053.
42.
Hubackova S, Krejcikova K, Bartek J, Hodny Z: Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells. J Biol Chem 2012;287:26702-26714.
43.
Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004;76:514-519.
44.
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-371.
45.
Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP: Endotoxin/lipopolysaccharide activates NF-kappaB and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol 2003;170:795-804.
46.
Costa C, Incio J, Soares R: Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007;10:149-166.
47.
McDonald DM: Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001;164:S39-S45.
48.
Rodriguez-Martinez S, Cancino-Diaz ME, Miguel PS, Cancino-Diaz JC: Lipopolysaccharide from Escherichia coli induces the expression of vascular endothelial growth factor via Toll-like receptor 4 in human limbal fibroblasts. Exp Eye Res 2006;83:1373-1377.
49.
Oken MM, Pomeroy C, Weisdorf D, Bennett JM: Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996;100:624-628.
50.
Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D, Dong Z: Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002;101:415-422.
51.
Oda K, Kitano H: A comprehensive map of the Toll-like receptor signaling network. Mol Syst Biol 2006;2:2006.0015.
52.
Yu L, Wang L, Chen S: Endogenous Toll-like receptor ligands and their biological significance. J Cell Mol Med 2010;14:2592-2603.
53.
Wong KF, Yuan Y, Luk JM: Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol 2012;39:311-320.
54.
Leibovich SJ, Chen JF, Pinhal-Enfield G, Belem PC, Elson G, Rosania A, Ramanathan M, Montesinos C, Jacobson M, Schwarzschild MA, Fink JS, Cronstein B: Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol 2002;160:2231-2244.
55.
Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005;204:27-42.
56.
Hara Y, Kuroda N, Inoue K, Sato T: Up-regulation of vascular endothelial growth factor expression by adenosine through adenosine a2 receptors in the rat tongue treated with endotoxin. Arch Oral Biol 2009;54:932-942.
57.
Akira S, Hemmi H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95.
58.
Akira S: Mammalian Toll-like receptors. Curr Opin Immunol 200315:5-11.
59.
Ogata H, Su I, Miyake K, Nagai Y, Akashi S, Mecklenbrauker I, Rajewsky K, Kimoto M, Tarakhovsky A: The Toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med 2000;192:23-29.
60.
Sethi G, Tergaonkar V: Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol Sci 2009;30:313-321.
61.
Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A: Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-terminal kinase. Blood 2003;102:1740-1742.
62.
Zhou YX, Huang YL: Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J (Engl) 2009;122:1666-1673.
63.
Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, Lam P, Kumar AP, Sethi G: Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 2011;16:1028-1041.
64.
Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Chng WJ, Sethi G: Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol 2011;164:1506-1521.
65.
Kim JH, Lee JO, Lee SK, Kim N, You GY, Moon JW, Sha J, Kim SJ, Park SH, Kim HS: Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway. Cell Signal 2013, 25:805-813.
66.
Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, Luk JM, Sethi G: Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) 2012;5:631-643.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.